Get started
Author

Vincent Li

ORCID: 0000-0003-1923-5232
Observed ORCID: 0000-0003-1923-5232
OpenAlex ID: A5015867139
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
2026 · Kohei Shitara, Elena Elimova, et al. · New England Journal of Medicine · 28
Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma
2025 · Keun-Wook Lee, Li-Yuan Bai, et al. · Clinical Cancer Research · 11
PDF
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
2022 · Julien Edeline, Philippe Merle, et al. · Journal of Clinical Oncology · 5
AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).
2022 · Jia Fan, Zhenggang Ren, et al. · Journal of Clinical Oncology · 3
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208.
2022 · Ann-Lii Cheng, Jinlin Hou, et al. · Journal of Clinical Oncology
Works count: 5
Citation count: 47
H-index: 3
I10-index: 2
Year
Topic
Type